Get the Stockscreener App
1.60
0.63%
0.01
Nyxoah Sa stock is traded at $1.60, with a volume of 280.53K.
It is up +0.63% in the last 24 hours and down -45.21% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$1.59
Open:
$1.64
24h Volume:
280.53K
Relative Volume:
1.08
Market Cap:
$159.88M
Revenue:
$17.85M
Net Income/Loss:
$-96.93M
P/E Ratio:
-0.6469
EPS:
-2.4735
Net Cash Flow:
$-88.29M
1W Performance:
+7.38%
1M Performance:
-45.21%
6M Performance:
-65.59%
1Y Performance:
-79.27%
1-Day Range:
$1.52
$1.64
1-Week Range:
$1.36
$1.70
52-Week Range:
$1.26
$8.5878
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
1.60 | 159.88M | 17.85M | -96.93M | -88.29M | -2.4735 |
ISRG
Intuitive Surgical Inc
|
406.78 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.98 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.68 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.94 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
188.63 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Nyxoah SA (NYXH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Publication relating to transparency notifications - GlobeNewswire
Nyxoah taps another $15M as it readies Genio U.S. launch - Stock Titan
Stifel cuts Nyxoah stock price target to $3 on capital concerns By Investing.com - Investing.com South Africa
Stifel cuts Nyxoah stock price target to $3 on capital concerns - Investing.com
Nyxoah SA (NYXH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nyxoah SA (NYXH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nyxoah SA (NYXH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
United StatesMintz Advises On Nyxoah’s $95 Million Public Offering - Mondaq
Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology - GlobeNewswire
Nyxoah Updates Capital Structure After Major Share Issuance - The Globe and Mail
Nyxoah SA (NYXH) may report negative earnings: Know the trend ahead of next week's release - MSN
Nyxoah (NASDAQ: NYXH) adds 55,232,558 new shares after US offering - Stock Titan
Cochlear (NYXH) reports 5.91% beneficial ownership in Nyxoah - Stock Titan
Nyxoah closes underwritten public offering - Medical Buyer
Nyxoah Raises $95 Million Through Public Stock Offering in the United States - Idéal Investisseur
Nyxoah Finalizes Capital Raise - marketscreener.com
Nyxoah issues 55.2M new shares after US public offering, raising total voting shares to nearly 100M. - Pluang
Nyxoah issues 55.2M new shares, boosting total voting rights to nearly 100M. - Pluang
Nyxoah raises $110 million to fund U.S. expansion of sleep apnea device By Investing.com - Investing.com South Africa
Information on the total number of voting rights and shares - GlobeNewswire
Nyxoah raises $110 million to fund U.S. expansion of sleep apnea device - Investing.com
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch - The Manila Times
Sleep apnea medtech Nyxoah lines up $110M for U.S. Genio push - Stock Titan
Nyxoah Announces Closing of Underwritten Public Offering - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Nyxoah Shares Slide 3.6% as Stock Approaches Key Support Level (NYXH)CTA Positioning - newsline.com
Nyxoah Launches $88.5 Million Underwritten Share Offering to Fund Genio OSA Expansion - The Globe and Mail
What's Going On With Nyxoah Stock Tuesday? - Benzinga
Nyxoah (NASDAQ: NYXH) raises $95M in U.S. share sale - Stock Titan
Nyxoah (NASDAQ: NYXH) raises ~$95M via 55.2M-share offering - Stock Titan
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering - marketscreener.com
Nyxoah 55.23M share Spot Secondary priced at $1.72 - TipRanks
Sleep apnea device firm Nyxoah prices $95M stock sale for U.S. push - Stock Titan
Nyxoah Begins Search for New US-based CEO - Moomoo
Nyxoah announces proposed offering of ordinary shares - Medical Buyer
Nyxoah Enters New Chapter of Long Term Value Creation - The Manila Times
Nyxoah announces offering of ordinary shares, no amount given - TipRanks
Nyxoah Launches U.S. CEO Search as Cash Runway Narrows and Patent Fight with Inspire Escalates - TipRanks
Nyxoah SA (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Pre-Revenue StageTax Rate Impact - newsline.com
Nyxoah (NYXH) files prospectus supplement for share offering, 30-day overallotment - Stock Titan
Nyxoah (NASDAQ: NYXH) outlines US growth, patent fight and cash runway - Stock Titan
Nyxoah Announces Proposed Offering of Ordinary Shares - marketscreener.com
NYXH Q1 2026 Earnings: Beat on EPS Despite No Revenue ReportedWeak Earnings Momentum - newsline.com
Nyxoah SA (NYXH) Gains Ground: Testing Key Resistance LevelsVolatility Term Structure - newsline.com
Nyxoah (NYXH) Slips 5.9% as Shares Test Support Near $2.56Factor Momentum - The Legal Advocate
Nyxoah (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Sleep Apnea PipelineEarnings Trend Analysis - The Legal Advocate
Nyxoah SA (NYXH) Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Sleep Apnea PlatformProfitability Analysis - The Legal Advocate
Nyxoah Q1 earnings call highlights - MSN
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):